The Directorate of Drugs Control, Punjab (DDCP), has issued the medicine stoppage alert, ordering a halt to the sale and use of two batches of a dexamethasone injection after inspectors found that the batches had entered the supply chain before the required quality-control testing had been completed.
The alert concerns Injection Davdax 1mL (Dexamethasone Sodium Phosphate 4mg/mL), registered under Reg. No. 121545. The affected batches are: DDI132 and DDI133.
According to the alert No. 140/2026 of DDC, the batches were released into the supply chain before completion of the required quality-control requirements for batch release, contrary to applicable Good Manufacturing Practices (GMP).
The authorities said the quality, safety and efficacy of the affected batches could not be assured while testing and investigation were still pending. The stoppage was therefore described as a precautionary regulatory measure.
Retailers, wholesalers, distributors, healthcare facilities and others holding the specified batches have been directed to immediately stop their sale, supply, dispensing, distribution and use.
Existing stocks should be quarantined, kept separately, and reported to the relevant Drug Inspector or Drug Inspector Distributor/Health Facility.
Healthcare providers have also been advised to monitor patients who may have received the affected batches and report any suspected adverse drug reactions through the pharmacovigilance system.
Patients who have already received the affected batches and have concerns are advised to contact their treating healthcare professional.
